Yousif Capital Management LLC Sells 658 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Yousif Capital Management LLC lowered its position in United Therapeutics Co. (NASDAQ:UTHR) by 3.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,367 shares of the biotechnology company’s stock after selling 658 shares during the quarter. Yousif Capital Management LLC’s holdings in United Therapeutics were worth $5,775,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of UTHR. USA Financial Formulas bought a new position in United Therapeutics in the third quarter worth $33,000. Brooklyn Investment Group bought a new position in shares of United Therapeutics during the 3rd quarter worth about $33,000. Capital Performance Advisors LLP acquired a new stake in shares of United Therapeutics during the 3rd quarter valued at about $82,000. MassMutual Private Wealth & Trust FSB increased its stake in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 58 shares during the period. Finally, Values First Advisors Inc. acquired a new position in United Therapeutics in the third quarter worth about $90,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 15,000 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $407.32, for a total transaction of $6,109,800.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Judy D. Olian sold 1,750 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $412.48, for a total value of $721,840.00. Following the completion of the sale, the director now directly owns 5,655 shares of the company’s stock, valued at approximately $2,332,574.40. This trade represents a 23.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 128,614 shares of company stock worth $47,868,005 in the last quarter. 11.90% of the stock is owned by company insiders.

United Therapeutics Stock Down 0.1 %

Shares of UTHR stock opened at $353.75 on Friday. The firm has a market cap of $15.79 billion, a price-to-earnings ratio of 15.54, a PEG ratio of 0.92 and a beta of 0.57. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82. The stock has a 50-day moving average price of $363.31 and a 200 day moving average price of $357.63.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. TD Cowen upped their price objective on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. LADENBURG THALM/SH SH increased their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Argus boosted their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. The Goldman Sachs Group increased their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. Finally, Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $382.08.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.